Novel Targets For Atherosclerosis Prevention

What’s New with TG and AngPTL3 – Aruna D. Pradhan, MD, MPH, MSc

What’s New with Lp(a) – Samia Mora, MD

What’s New with LDL and ApoB – Jorge Plutzky, MD

What’s New with Inflammatory Targets – Paul M. Ridker, MD, MPH

Discussion/Q&A – John F. Keaney, Jr., MD – Moderator

Peripheral Arterial Disease

PAD – Pathways for Optimizing Cardiovascular and Limb Outcomes – Marc P. Bonaca, MD, MPH

Discussion/Q&A – Marie D. Gerhard-Herman, MD – Moderator

Heart Failure

Heart Failure and Venous Thromboembolism – Samuel Z. Goldhaber, MD

More Than Just Diabetes and Heart Failure – SGLT2 – Deepak L. Bhatt, MD, MPH

More Than Just Diabetes and Heart Failure – GLP1 – Brendan M. Everett, MD, MPH

Heart Failure – Reduced Ejection Fraction – Marc A. Pfeffer, MD, PhD

Discussion/Q&A – Akshay Suvas Desai, MD, MPH – Moderator

Heart Failure – Preserved Ejection Fraction – Scott D. Solomon, PhD

Heart Failure – Middle-of-the-Road Ejection Fraction – Navigating the Alphabet Soup – Michele A. Hamilton, MD

CMR Imaging of Imaging of Heart Failure – Raymond Y. Kwong, MD, MPH

Atrial Fibrillation & Coronary Disease

Dual Antiplatelet Therapy and Anticoagulation – Michelle L. O’Donoghue, MD, MPH

How to Manage the Anticoagulation Around Ablation and Cardioversions and Watchmans for AF – Bruce A. Koplan, MD

Anticoagulation

Dose-Reduced Direct Oral Anticoagulants – Efficacy and Safety – Behnood Bikdeli, MD, MS

Duration of Anticoagulation – Arterial Thrombosis – Navigating Limitations in Data and Variations in Practice – Teresa Carman, MD, RPVI, MSVM

Duration of Anticoagulation – Venous Thrombosis – Gregory Piazza, MD, MS

Novel Anticoagulation Targets – Factor XI and XII Inhibitors – Jeffrey I. Weitz, MD

Discussion/Q&A – Samuel Z. Goldhaber, MD – Moderator

Racial Disparities In Arterial And Venous Thrombosis

Racial Disparities in Healthcare – Cassandra M. Pierre, MD, MSc

Racial Disparities in Arterial and Venous Thrombosis – Karlyn A. Martin, MD

Discussion/Q&A – Gregory Piazza, MD, MS – Moderator

Genetics

VTE Prediction – Using Genetics as a Powerful Tool – Nicholas A. Marston, MD, MPH

Clonal Hematopoiesis of Indeterminate Potential (CHIP) – Association with VTE & PAD – Peter Libby, MD

Discussion/Q&A – Gregory Piazza, MD, MS – Moderator

Covid And Thrombosis

COVID and Thrombosis – Mechanisms and Epidemiology – Gregory Piazza, MD, MS

Prevention of VTE in COVID-19 Patients – Behnood Bikdeli, MD, MS

Discussion/Q&A – Samuel Z. Goldhaber, MD – Moderator

VTE Prevention

VTE Prophylaxis for Orthopedic Surgery – Samuel Z. Goldhaber, MD

Discussion/Q&A – Ebrahim Barkoudah, MD, MPH – Moderator

PE Reperfusion

Device Therapy for PE Reperfusion – Navigating a Rapidly Changing Landscape – Gregory Piazza, MD, MS

Systemic Fibrinolysis (PEITHO-3) – Samuel Z. Goldhaber, MD

Adventures with Hypertrophic Cardiomyopathy – 1958-2022 – Eugene Braunwald, MD

Pulmonary Hypertension and Thrombosis

Chronic Thromboembolic Pulmonary Hypertension – Bradley A. Maron, MD

Pulmonary Hypertension After PE That is Not Chronic Thromboembolic Pulmonary Hypertension – Jane A. Leopold, MD, FACC, FAHA, FSCAIc

Post-Thrombotic Syndrome

Post-thrombotic Syndrome – Epidemiology and Medical Therapy – Susan R. Kahn, MD, MSc, FRCPC, ABIM

Intervention, Acute Intervention, and Chronic Venous Obstructive Disease – Suresh Vedantham, MD

Discussion/Q&A – Arvind K. Pandey, MD – Moderator

VTE and Cancer

Vascular Cardio-Oncology – Javid Moslehi, MD

Prevention of Thrombotic Complications of Cancer and Cancer Therapy – Simon Mantha, MD, MPH

Treatment of Cancer-Associated Thrombosis – Michael B. Streiff, MD

Discussion/Q&A – Jean Connors, MD – Moderator